Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 10/20 | 0.41 |
| ▸ | LCLAT1 | Q6UWP7 | 1/20 | 0.37 |
| ▸ | HTR2A | P28223 | 2/20 | 0.36 |
| ▸ | GSK3B | P49841 | 8/20 | 0.36 |
| ▸ | FGFR3 | P22607 | 5/20 | 0.36 |
| ▸ | KDR | P35968 | 4/20 | 0.36 |
| ▸ | WNT1 | P04628 | 4/20 | 0.35 |
| ▸ | CLK2 | P49760 | 1/20 | 0.35 |
| ▸ | CLK3 | P49761 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | FYN | P06241 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7117409 | 1.00 | DYRK1A (0.41) | DYRK1ALCLAT1HTR2AGSK3BFGFR3 | |
| SCHEMBL7128690 | 0.91 | DYRK1A (0.40) | DYRK1ALCLAT1HTR2AGSK3BFGFR3 | |
| SCHEMBL7128685 | 0.91 | DYRK1A (0.40) | DYRK1ALCLAT1HTR2AGSK3BFGFR3 | |
| SCHEMBL7120271 | 0.86 | DYRK1A (0.51) | DYRK1ALCLAT1GSK3BFGFR3KDR | |
| SCHEMBL7122934 | 0.82 | FYN (0.42) | DYRK1AGSK3BFGFR3KDRWNT1 | |
| SCHEMBL7122931 | 0.82 | FYN (0.42) | DYRK1AGSK3BFGFR3KDRWNT1 | |
| SCHEMBL7121297 | 0.82 | FYN (0.40) | DYRK1AGSK3BFGFR3KDRFYN | |
| SCHEMBL7121293 | 0.82 | FYN (0.40) | DYRK1AGSK3BFGFR3KDRFYN | |
| SCHEMBL7117412 | 0.81 | DYRK1A (0.39) | DYRK1AGSK3BWNT1CLK2CLK3 | |
| SCHEMBL7980096 | 0.78 | DYRK1A (0.51) | DYRK1ALCLAT1GSK3BFGFR3KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030176454-A1 | N-coating heterocyclic compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-09-18 | — | — | US | disclosed |
| WO-2001087845-A2 | N-CONTAINING HETEROCYCLIC COMPOUNDS AND THEIR USE AS 5-HT ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-11-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030176454-A1 | N-coating heterocyclic compounds | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, GNE, NIT2 | DYRK1A 3357/4885LCLAT1 3815/4885HTR2A 429/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.